Skip to main
ELVN
ELVN logo

ELVN Stock Forecast & Price Target

ELVN Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enliven Therapeutics Inc. is implementing cost-saving measures, including a workforce reduction, which reflects prudent financial management in a challenging biotechnology sector. The company is strategically focusing on the development of its HER3-targeting ADC, EO-1022, which may result in significant future revenue opportunities starting in 2031. Additionally, the adjustments made to the financial model, including a focus on early-stage products and expense management, suggest that the company is positioning itself for a more stable financial trajectory.

Bears say

Enliven Therapeutics has recently decided to discontinue the development of its Claudin 18.2-targeting ADC, EO-3021, due to its lower-than-expected efficacy in a Phase 1 study, which raises concerns about the viability of this product candidate. This decision indicates a potential setback in Enliven's pipeline, as the comparatively low efficacy may deter further investment despite the drug being well tolerated. Additionally, the revision of the 12-month price target down to $1.00 from $6.00 suggests a significant decline in confidence regarding the company's future financial performance and product development prospects.

ELVN has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enliven Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enliven Therapeutics Inc (ELVN) Forecast

Analysts have given ELVN a Strong Buy based on their latest research and market trends.

According to 5 analysts, ELVN has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enliven Therapeutics Inc (ELVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.